Peptide Monographs

Leuprolide

Leuprolide is a peptide, indexed here under Endocrine and immune signalling peptides.

Identity

Measured identity values, each with the source that reports it
FieldValue
ClassificationPeptide
Primary classEndocrine and immune signalling peptides
CAS registry number53714-56-0[1]
PubChem CID657181[1]
UniProt accessionUnknown No UniProt query was run in v1.
Molecular formulaC59H84N16O12[1]
Molecular weight1209.4 g/mol[1]
Amino-acid sequenceUnknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1.
Reported half-lifeUnknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated.

What the cited literature examines

Leuprolide, also reported as leuprorelin, is a synthetic analogue of gonadotropin-releasing hormone. The Drugs@FDA register returned approved applications under this generic name; those products are recorded in the regulatory status field and are not what this page describes. A 1984 New England Journal of Medicine paper compares it with diethylstilbestrol in metastatic prostate cancer, a 1989 paper in the same journal reports a controlled trial with and without flutamide in prostatic carcinoma, and a 2014 Journal of Clinical Oncology paper reports intense androgen deprivation with abiraterone and leuprolide in localised high-risk disease.

Gynaecological records include a 1990 Fertility and Sterility randomised placebo-controlled study of the depot formulation in endometriosis, a 2010 Human Reproduction comparison with dienogest, a 2012 New England Journal of Medicine comparison with ulipristal acetate in uterine fibroids, and 1991 and 2001 Fertility and Sterility papers in in vitro fertilisation. Formulation records from 1988 and 1997 describe microcapsule and injectable microsphere depots, and a 2003 Nature Medicine paper reports leuprorelin in a transgenic mouse model of spinal and bulbar muscular atrophy.

[3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]

Reported mechanism

A gonadotropin-releasing hormone superagonist; the retrieved records report androgen and oestrogen suppression after sustained-release administration.

[12, 5]

Stated in the titles of the cited 1997 Advanced Drug Delivery Reviews and 2014 Journal of Clinical Oncology papers.

Targets named in the cited records: GnRH receptor.

FDA application register

A query of the FDA Drugs@FDA application register on 2026-10-09 returned 21 application record(s) for this compound name (including ANDA215336, NDA211488, NDA020011, ANDA217437, NDA021488, marketed as LEUPROLIDE ACETATE, CAMCEVI KIT, LUPRON DEPOT, ELIGARD KIT). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[2]

Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.

Retrieved 2026-10-09.

Amounts reported in the cited literature

Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.

No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.

Adverse effects reported in the cited literature

Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.

No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.

Other names

Leuprolide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.

Where this page sits

Research records

Cited research records for Leuprolide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.

Compounds indexed next to it

Class page: Endocrine and immune signalling peptides. Full index: all indexed compounds.

Questions this page answers

What does the cited literature examine for Leuprolide?

Leuprolide, also reported as leuprorelin, is a synthetic analogue of gonadotropin-releasing hormone. The Drugs@FDA register returned approved applications under this generic name; those products are recorded in the regulatory status field and are not what this page describes.

Which class is Leuprolide indexed under?

Leuprolide is indexed under Endocrine and immune signalling peptides. This class groups peptides whose retrieved literature concerns endocrine or immune signalling outside the growth hormone axis.

What does the FDA application register show for Leuprolide?

A query of the FDA Drugs@FDA application register on 2026-10-09 returned 21 application record(s) for this compound name (including ANDA215336, NDA211488, NDA020011, ANDA217437, NDA021488, marketed as LEUPROLIDE ACETATE, CAMCEVI KIT, LUPRON DEPOT, ELIGARD KIT). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.

Sources

  1. PubChem Compound Summary for CID 657181, Leuprolide. PubChem, National Library of Medicine (2026). pubchem:657181
  2. Drugs@FDA application register query for this compound, 21 application(s) returned: ANDA215336, NDA211488, NDA020011, ANDA217437, NDA021488. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:leuprolide
  3. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The New England journal of medicine (1984). pmid:6436700
  4. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. The New England journal of medicine (1989). pmid:2503724
  5. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). pmid:25311217
  6. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertility and sterility (1990). pmid:2118858
  7. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human reproduction (Oxford, England) (2010). pmid:20089522
  8. Ulipristal acetate versus leuprolide acetate for uterine fibroids. The New England journal of medicine (2012). pmid:22296076
  9. Serum progesterone levels predict success of in vitro fertilization/embryo transfer in patients stimulated with leuprolide acetate and human menopausal gonadotropins. The Journal of clinical endocrinology and metabolism (1991). pmid:1909704
  10. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and sterility (2001). pmid:11163814
  11. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chemical & pharmaceutical bulletin (1988). pmid:3136939
  12. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Advanced drug delivery reviews (1997). pmid:10837564
  13. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nature medicine (2003). pmid:12754502

On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.

Further reading